The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11151 malaria professionals are enjoying the free benefits of MalariaWorld today


NOT Open Access | An antibody for malaria prevention

September 8, 2021 - 17:11 -- NOT Open Access
O'Leary K
Nat Med. 2021 Sep 6

Despite existing public-health measures, the incidence of malaria is increasing in many regions. Malaria causes nearly 400,000 deaths annually; new measures are therefore urgently needed to help control this disease

NOT Open Access | Antibody acts like short-term malaria vaccine

August 25, 2021 - 15:50 -- NOT Open Access
Cohen J
Science. 2021 Aug 20;373(6557):843

A powerful new weapon could one day join the global fight against malaria, especially to help people who need temporary protection from the deadly disease. Drugs and bed nets can to some extent already protect against the disease, which still sickens at least 200 million people a year and kills an estimated 400,000. Vaccines have also shown some promise.

A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity

November 4, 2020 - 15:59 -- Open Access
Thai E, Costa G, Levashina EA, et al.
J Exp Med. 2020 Nov 2;217(11):e20200061

Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).

Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination

November 3, 2020 - 14:42 -- Open Access
Thompson HA, Hogan AB, Walker PGT, White MT, Cunnington AJ, Ockenhouse CF, Ghani AC
Vaccine. 2020 Nov 3;38(47):7498-7507

Anti-circumsporozoite antibody titres have been established as an essential indicator for evaluating the immunogenicity and protective capacity of the RTS,S/AS01 malaria vaccine.

Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response

October 15, 2020 - 08:50 -- Open Access
McNamara HA, Idris AH, Cockburn IA, et al.
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7

Generating sufficient antibody to block infection is a key challenge for vaccines against malaria. Here, we show that antibody titers to a key target, the repeat region of the Plasmodium falciparum circumsporozoite protein (PfCSP), plateaued after two immunizations in a clinical trial of the radiation-attenuated sporozoite vaccine. To understand the mechanisms limiting vaccine responsiveness, we developed immunoglobulin (Ig)-knockin mice with elevated numbers of PfCSP-binding B cells.

ITEM-THREE analysis of a monoclonal anti-malaria antibody reveals its assembled epitope on the pfMSP119 antigen

September 1, 2020 - 10:05 -- Open Access
Opuni KFM, Koy C, Russ M, Reepmeyer M, Danquah BD, Weresow M, Alef A, Lorenz P, Thiesen HJ, Glocker MO
J Biol Chem. 2020 Aug 26:jbc.RA120.014802

Rapid diagnostic tests are first line assays for diagnosing infectious diseases, such as malaria. To minimize false positive and false negative test results in population screening assays, high quality reagents and well characterized antigens and antibodies are needed. An important property of antigen - antibody binding is recognition specificity which best can be estimated by mapping an antibody's epitope on the respective antigen.

Evaluation of antibody responses to the early transcribed membrane protein family in Plasmodium vivax

January 15, 2020 - 09:24 -- Open Access
Lee SK, Han JH, Park JH, Ha KS, Park WS, Hong SH, Na S, Cheng Y, Han ET
Parasites & Vectors volume, 2019 Dec 19; 12(1):594.

Malaria parasites form intracellular membranes that separate the parasite from the internal space of erythrocytes, and membrane proteins from the parasites are exported to the host via the membrane. In our previous study, Plasmodium vivax early transcribed membrane protein (PvETRAMP) 11.2, an intracellular membrane protein that is highly expressed in blood-stage parasites, was characterized as a highly immunogenic protein in P. vivax malaria patients. However, the other PvETRAMP family proteins have not yet been investigated. In this study, PvETRAMPs were expressed and evaluated to determine their immunological profiles.

Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein

January 15, 2020 - 07:51 -- Open Access
Pholcharee T, Oyen D, Torres JL, Flores-Garcia Y, Martin GM, González-Páez GE, Emerling D, Volkmuth W, Locke E, King CR, Zavala F, Ward AB, Wilson IA
J Mol Biol. 2019 Dec 27. pii: S0022-2836(19)30738-7

Malaria vaccine candidate RTS,S/AS01 is based on the central and C-terminal regions of the circumsporozoite protein (CSP) of P. falciparum. mAb397 was isolated from a volunteer in an RTS,S/AS01 clinical trial, and it protects mice from infection by malaria sporozoites. However, mAb397 originates from the less commonly used VH3-15 germline gene compared to the VH3-30/33 antibodies generally elicited by RTS,S to the central NANP repeat region of CSP. The crystal structure of mAb397 with an NPNA4 peptide shows that the central NPNA forms a type I β-turn and is the main recognition motif.

Subscribe to RSS - antibody